Cargando…
Tocilizumab is recommended for the treatment of severe COVID-19
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540282/ https://www.ncbi.nlm.nih.gov/pubmed/33038768 http://dx.doi.org/10.1016/j.ebiom.2020.103045 |
| _version_ | 1783591172239785984 |
|---|---|
| author | Zhou, Yonggang Wei, Haiming |
| author_facet | Zhou, Yonggang Wei, Haiming |
| author_sort | Zhou, Yonggang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7540282 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75402822020-10-08 Tocilizumab is recommended for the treatment of severe COVID-19 Zhou, Yonggang Wei, Haiming EBioMedicine Commentary Elsevier 2020-10-07 /pmc/articles/PMC7540282/ /pubmed/33038768 http://dx.doi.org/10.1016/j.ebiom.2020.103045 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Commentary Zhou, Yonggang Wei, Haiming Tocilizumab is recommended for the treatment of severe COVID-19 |
| title | Tocilizumab is recommended for the treatment of severe COVID-19 |
| title_full | Tocilizumab is recommended for the treatment of severe COVID-19 |
| title_fullStr | Tocilizumab is recommended for the treatment of severe COVID-19 |
| title_full_unstemmed | Tocilizumab is recommended for the treatment of severe COVID-19 |
| title_short | Tocilizumab is recommended for the treatment of severe COVID-19 |
| title_sort | tocilizumab is recommended for the treatment of severe covid-19 |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540282/ https://www.ncbi.nlm.nih.gov/pubmed/33038768 http://dx.doi.org/10.1016/j.ebiom.2020.103045 |
| work_keys_str_mv | AT zhouyonggang tocilizumabisrecommendedforthetreatmentofseverecovid19 AT weihaiming tocilizumabisrecommendedforthetreatmentofseverecovid19 |